CG Oncology Inc
CGON39.840USD
-0.300-0.75%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
3.12BMarket Cap
LossP/E TTM
More Details of CG Oncology Inc Company
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
CG Oncology Inc Info
Ticker SymbolCGON
Company nameCG Oncology Inc
IPO dateJan 25, 2024
CEOKuan (Arthur)
Number of employees113
Security typeOrdinary Share
Fiscal year-endJan 25
Address400 Spectrum Center Drive
CityIRVINE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92618
Phone19492886298
Websitehttps://www.cgoncology.com/
Ticker SymbolCGON
IPO dateJan 25, 2024
CEOKuan (Arthur)
Company Executives of CG Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Arthur Kuan
Mr. Arthur Kuan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
36.15K
--
Dr. Brian Liu, M.D.
Dr. Brian Liu, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua F. Patterson
Mr. Joshua F. Patterson
Chief Compliance Officer, General Counsel and Secretary
Chief Compliance Officer, General Counsel and Secretary
--
--
Dr. James J. Mule, Ph.D.
Dr. James J. Mule, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ambaw Bellete
Mr. Ambaw Bellete
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Susan Graf
Ms. Susan Graf
Independent Director
Independent Director
--
--
Mr. Jim DeTore
Mr. Jim DeTore
Interim Principal Financial and Accounting Officer
Interim Principal Financial and Accounting Officer
--
--
Dr. Leonard Post, Ph.D.
Dr. Leonard Post, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Vijay Kasturi, M.D.
Dr. Vijay Kasturi, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Victor Tong, Jr.
Mr. Victor Tong, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Arthur Kuan
Mr. Arthur Kuan
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
36.15K
--
Dr. Brian Liu, M.D.
Dr. Brian Liu, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua F. Patterson
Mr. Joshua F. Patterson
Chief Compliance Officer, General Counsel and Secretary
Chief Compliance Officer, General Counsel and Secretary
--
--
Dr. James J. Mule, Ph.D.
Dr. James J. Mule, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ambaw Bellete
Mr. Ambaw Bellete
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Susan Graf
Ms. Susan Graf
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.14%
Decheng Capital LLC
7.90%
Wellington Management Company, LLP
6.83%
Longitude Capital Management Co., LLC
5.78%
BlackRock Institutional Trust Company, N.A.
4.90%
Other
66.45%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
8.14%
Decheng Capital LLC
7.90%
Wellington Management Company, LLP
6.83%
Longitude Capital Management Co., LLC
5.78%
BlackRock Institutional Trust Company, N.A.
4.90%
Other
66.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.69%
Investment Advisor/Hedge Fund
27.61%
Venture Capital
18.12%
Hedge Fund
17.57%
Private Equity
6.14%
Research Firm
2.80%
Corporation
1.88%
Individual Investor
1.10%
Bank and Trust
0.51%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
353
88.33M
117.40%
+455.04K
2025Q3
350
87.87M
123.86%
+2.02M
2025Q2
317
85.74M
114.31%
+5.21M
2025Q1
280
79.88M
105.62%
-622.93K
2024Q4
251
75.20M
83.92%
+13.24M
2024Q3
213
61.46M
82.60%
+7.92M
2024Q2
181
53.14M
65.27%
+4.99M
2024Q1
132
48.62M
34.57%
+25.58M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
5.90M
7.73%
+70.19K
+1.20%
Jun 30, 2025
Decheng Capital LLC
6.37M
8.36%
--
--
Jun 30, 2025
Wellington Management Company, LLP
1.90M
2.49%
-226.31K
-10.65%
Jun 30, 2025
Longitude Capital Management Co., LLC
4.66M
6.11%
--
--
Sep 11, 2025
BlackRock Institutional Trust Company, N.A.
3.82M
5.01%
-41.95K
-1.09%
Jun 30, 2025
Fidelity Management & Research Company LLC
3.72M
4.88%
+1.30M
+53.90%
Jun 30, 2025
TCG Crossover Management, LLC
3.67M
4.81%
--
--
Jun 30, 2025
ORI Capital Limited
3.58M
4.7%
-10.40K
-0.29%
Apr 08, 2025
Braidwell LP
3.28M
4.31%
--
--
Jun 30, 2025
Foresite Capital Management, LLC
3.23M
4.23%
+145.00K
+4.71%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
1.79%
ALPS Medical Breakthroughs ETF
1.41%
Virtus LifeSci Biotech Clinical Trials ETF
1.11%
Global X Aging Population ETF
0.75%
State Street SPDR S&P Biotech ETF
0.65%
First Trust Small Cap Growth AlphaDEX Fund
0.64%
JPMorgan Healthcare Leaders ETF
0.61%
Goldman Sachs Future Health Care Equity ETF
0.59%
ProShares Ultra Nasdaq Biotechnology
0.42%
Direxion Daily S&P Biotech Bull 3X Shares
0.4%
View more
Tema Oncology ETF
Proportion1.79%
ALPS Medical Breakthroughs ETF
Proportion1.41%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.11%
Global X Aging Population ETF
Proportion0.75%
State Street SPDR S&P Biotech ETF
Proportion0.65%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.64%
JPMorgan Healthcare Leaders ETF
Proportion0.61%
Goldman Sachs Future Health Care Equity ETF
Proportion0.59%
ProShares Ultra Nasdaq Biotechnology
Proportion0.42%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.4%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CG Oncology Inc?
The top five shareholders of CG Oncology Inc are:
The Vanguard Group, Inc. holds 5.90M shares, accounting for 7.73% of the total shares.
Decheng Capital LLC holds 6.37M shares, accounting for 8.36% of the total shares.
Wellington Management Company, LLP holds 1.90M shares, accounting for 2.49% of the total shares.
Longitude Capital Management Co., LLC holds 4.66M shares, accounting for 6.11% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.82M shares, accounting for 5.01% of the total shares.
The Vanguard Group, Inc. holds 5.90M shares, accounting for 7.73% of the total shares.
Decheng Capital LLC holds 6.37M shares, accounting for 8.36% of the total shares.
Wellington Management Company, LLP holds 1.90M shares, accounting for 2.49% of the total shares.
Longitude Capital Management Co., LLC holds 4.66M shares, accounting for 6.11% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.82M shares, accounting for 5.01% of the total shares.
What are the top three shareholder types of CG Oncology Inc?
The top three shareholder types of CG Oncology Inc are:
The Vanguard Group, Inc.
Decheng Capital LLC
Wellington Management Company, LLP
The Vanguard Group, Inc.
Decheng Capital LLC
Wellington Management Company, LLP
How many institutions hold shares of CG Oncology Inc (CGON)?
As of 2025Q4, 353 institutions hold shares of CG Oncology Inc, with a combined market value of approximately 88.33M, accounting for 117.40% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -6.46%.
What is the biggest source of revenue for CG Oncology Inc?
In FY2025Q2, the -- business generated the highest revenue for CG Oncology Inc, amounting to -- and accounting for --% of total revenue.
